When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease

Author:

Systrom Hannah K.1,Rai Victoria2ORCID,Singh Siddharth3,Baidoo Leonard4,Cheifetz Adam S.5,Devlin Shane M.6ORCID,Gecse Krisztina B.7,Irving Peter M.8ORCID,Kaplan Gilaad G.6ORCID,Kozuch Patricia L.9ORCID,Ullman Thomas10,Sparrow Miles P.11,Melmed Gil Y.12ORCID,Siegel Corey A.1ORCID

Affiliation:

1. Dartmouth Hitchcock Medical Center, Division of Gastroenterology and Hepatology, Lebanon, New Hampshire USA;

2. Yale School of Medicine, New Haven, Connecticut USA;

3. University of California San Diego, Division of Gastroenterology, San Diego, California USA;

4. University of Tennessee College of Medicine, Inflammatory Bowel Disease Center, Memphis, Tennessee USA;

5. Beth Israel Deaconess Medical Center, Inflammatory Bowel Disease Center, Boston, Massachusetts, USA;

6. University of Calgary, Inflammatory Bowel Disease Centre, Calgary, Alberta, Canada;

7. Amsterdam University Medical Center, Gastroenterology, Amsterdam, Netherlands;

8. Guy's and St. Thomas' Hospitals, Gastroenterology, London, United Kingdom;

9. Jefferson University, Division of Gastroenterology, Philadelphia, Pennsylvania, US;

10. Montefiore Medical Center, Division of Gastroenterology, Bronx, New York, USA;

11. The Alfred Hospital, IBD Unit, Melbourne, Victoria, Australia;

12. Cedars-Sinai Medical Center, Inflammatory Bowel Disease Center, Los Angeles, California USA.

Abstract

BACKGROUND: A treat-to-target strategy for inflammatory bowel disease (IBD) recommends iterative treatment adjustments to achieve clinical and endoscopic remission. In asymptomatic patients with ongoing endoscopic activity, the risk/benefit balance of this approach is unclear, particularly with prior exposure to advanced therapies. METHODS: Using the RAND/University of California Los Angeles Appropriateness Method, 9 IBD specialists rated appropriateness of changing therapy in 126 scenarios of asymptomatic patients with ulcerative colitis and Crohn's disease and active endoscopic disease. Disease extent and behavior, prior treatment, prior complications, and recent disease progression were considered, as were factors that might influence decision-making, including age and pregnancy. Ratings were collected through anonymous survey, discussed at an in-person meeting, and finalized in a second anonymous survey. RESULTS: Panelists rated change in therapy as appropriate (i.e., expected benefit sufficiently outweighs potential harms from continuing therapy) in 96/126 scenarios, generally in patients with progressive, complicated, and/or extensive disease, while changing therapy was rated uncertain in 27 scenarios of mild and/or stable disease. Changing therapy was rated inappropriate in ulcerative colitis patients with mild and stable disease previously exposed to ≥3 therapies or with improved endoscopic activity, and in Crohn's disease patients with only scattered aphthous ulcers. The validated threshold for disagreement was not crossed for any scenario. Patient age older than 65 years and a plan for pregnancy in the next year might influence decision-making in some settings. DISCUSSION: Appropriateness ratings can help guide clinical decision-making about changing therapy to achieve endoscopic remission in asymptomatic patients with IBD until data from ongoing randomized studies are available.

Funder

The BRIDGe Group

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3